Takeda India recognized as Top Employer for the Third Consecutive Year
By Pinkerala News Desk | Jan 20, 2023
Takeda India recognized as Top Employer for the Third Consecutive Year
- Global recognition and Top Employer Certification received in 22 Countries from Top Employers Institute
− Takeda is one of the 15 companies to receive Global Top Employer® certification for 2023
New Delhi, January 19, 2023 – Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.), a global values-based, R&D-driven biopharmaceutical leader, has been recognized as a Top Employer by the Top Employers Institute for the third consecutive year. Takeda was also certified as the global Top Employer for 2023, making it the sixth consecutive year in a row for Takeda globally.
Additionally, Takeda has been recognized as a top employer across 22 countries strengthening its commitment to creating a diverse, equitable, and inclusive working environment and an exceptional employee experience. Takeda is among 15 companies worldwide to receive global certification for the year 2023.
On being a recipient of the Top Employer certification 2023, Ms Serina Fischer, General Manager, Takeda Biopharmaceuticals India Private Limited said, “We are delighted to have been named as the Top Employer for the third consecutive year. This accolade by the Top Employers Institute® is reflective of our people practices benchmarked against the best in the industry. We strive to create a working environment where our teams feel valued, and respected and are empowered to make a meaningful difference in the lives of patients. We are committed to providing our employees with the support, resources, and opportunities they need to grow and excel in their careers, and we will continue to work towards maintaining our position as a top employer in the pharmaceutical industry."
Mr. Anoop Kamat, Head of Human Resources, Takeda Biopharmaceuticals India Private Limited added, “We are committed to fostering a culture of collaboration, diversity, equity, and inclusion to create exceptional employee experiences. Our participation in the Top Employer certification also helps us evaluate our people practices and provides insights into our strengths and opportunities for continual improvement. We are proud of this achievement and remain committed to creating a culture that enables success for the excellent talent we have at Takeda.”
Takeda excelled in the areas of Ethics & Integrity, Purpose & Values, Business Strategy, Employer Branding and Organization & Change. Each of the 22 Takeda countries and regions that participated in the Top Employer survey received certification, including Canada for the first time. The full list of countries where Takeda was named a Top Employer is below:
- Asia Pacific: Australia, China, India, Japan, South Korea
- Europe: Austria, France, Germany, Ireland, Italy, Poland, Portugal, Spain, Switzerland, United Kingdom.
- Latin America: Argentina, Brazil, Colombia, Mexico
- Middle East: Israel
- North America: Canada and United States
“Exceptional times bring out the best in people and organizations. And we have witnessed this in our Top Employers Certification Program this year: an exceptional performance from the certified Top Employers 2023. And amongst this community of outstanding organizations, Takeda, has proven its commitment to its employees on a global scale,” said David Plink, chief executive officer, Top Employers Institute. “This consistency in people practices across the globe characterizes an exclusive group of companies that have achieved a global certification through the Top Employers Program. We are proud to announce and celebrate these companies and their achievement in 2023.”
The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. This survey covers six HR domains consisting of 20 topics including People Strategy, Work Environment, Talent Acquisition, Learning, Diversity & Inclusion, Well-being and more. Takeda India achieved the prestigious Great Place to Work® Certification in February 2022 and receiving it for the third year, promisingly reiterates Takeda India’s efforts to establish an employee-first approach and create a diverse and inclusive work culture.
To learn more about Top Employers Institute and the Top Employers certification, please visit: https://www.top-employers.com.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com .
+91 99712 90164
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
TAKEDA® Logo Disclaimer
TAKEDA®/TAKEDA Logo® (or actual logo) are registered trademarks of Takeda Pharmaceutical Company Limited.
By Pinkerala | Jan 28, 2023World Benchmark Study ranks KSUM among world’s top five incubators
By Pinkerala | Jan 28, 2023Equitas Small Finance Bank opens 7 new branches in one day and lives to its Power of 7 Mantra
By Pinkerala | Jan 28, 2023India achieves complete transition to T+1 Settlement Cycle in Equity Markets
By Pinkerala | Jan 28, 2023